Related references
Note: Only part of the references are listed.The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial
P. L. Chen et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex The TREATMENT Randomized Clinical Trial
Mary Kay Koenig et al.
JAMA DERMATOLOGY (2018)
Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex A Randomized Clinical Trial
Mari Wataya-Kaneda et al.
JAMA DERMATOLOGY (2017)
An estimation of the incidence of tuberous sclerosis complex in a nationwide retrospective cohort study (1997-2010)
C. -H. Hong et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus
Neera Nathan et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis
Shaowei Li et al.
NATURE COMMUNICATIONS (2011)
Transforming growth factor-β enhances matrix metalloproteinase-2 expression and activity through AKT in fibroblasts derived from angiofibromas in patients with tuberous sclerosis complex
C. -H. Lee et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Share Paper
